Apalutamide was well-tolerated and associated with delayed metastasis in men with high-risk castration-resistant prostate cancer that has become refractory to conventional hormone therapy, according to an early interim analysis of the phase III SPARTAN clinical trial.
Adding atezolizumab and bevacizumab to standard care was tolerable and slowed tumor growth in patients with previously untreated clear-cell or sarcomatoid-histology metastatic renal cell carcinoma when compared to sunitinib, according to findings from a phase III study.
Last year saw the first two FDA approvals of oncology biosimilars, but experts have voiced concerns about the emerging US biosimilars market, particularly regarding clinical uptake and uncertainty about costs.
Pfizer’s rituximab investigational biosimilar PF-05280586 met the primary endpoint of overall response rate equivalence to rituximab-EU (MabThera) as a frontline treatment for patients diagnosed with CD20-positive follicular lymphoma, the company announced.
Do you know which molecular markers signify poor-risk disease in AML? And how about what makes AML a challenging disease to manage in older adult patients? Test your knowledge in our latest quiz.
Immunochemotherapy should remain the standard induction approach for patients with high-risk follicular lymphoma.
Which somatic mutation do most high-grade serous ovarian carcinomas harbor? And what percentage of endometrioid endometrial tumors have copy-number alterations? Test your knowledge in our latest quiz.
Is the use of bisphosphonates in patients with multiple myeloma associated with improved progression-free or overall survival? Is hypertension a risk factor for carfilzomib-related cardiopulmonary toxicities? Test your knowledge in our latest quiz.
Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.
Treatment of previously untreated follicular lymphoma with atezolizumab combined with obinutuzumab and bendamustine was associated with widespread adverse events and a treatment-related death, according to an interim analysis of a phase Ib/II cohort study.